Carole Ho Biography and Net Worth

Insider of Denali Therapeutics

Carole Ho is our Chief Medical Officer and Head of Development. At Denali, Carole has built an integrated Development organization that is responsible for advancing therapeutic candidates from pre-IND enabling studies through Phase 1 to Phase 3 clinical trials. Under Carole’s leadership, her team has delivered on Denali’s biomarker driven development strategy to enable early target and pathway engagement in the clinic for therapeutics in development for Parkinson’s disease, Alzheimer's disease, and ALS.

Carole previously served as Vice President of Genentech Early Clinical Development and was responsible for delivery of pivotal trial-ready drug candidates in Neurology, Ophthalmology, Immunology, and Infectious Disease. During her 8-year tenure at Genentech, Carole held roles with leadership responsibility across multiple early- and late-stage clinical programs including Rituxan® for Wegener’s granulomatosis and microscopic polyangiitis, ocrelizumab for Multiple Sclerosis, lampalizumab for dry AMD, and crenezumab for Alzheimer’s Disease. At Genentech, in collaboration with Banner Health, Carole's team led the initiation of the world's first prevention trial in Alzheimer's disease in participants at risk for dementia due to a genetic mutation.

Carole completed her residency in Neurology at Harvard Medical School at the Massachusetts General Hospital / Brigham and Women’s Hospital, where she also served as Chief Resident. She obtained her M.D. from Cornell University and S.B. in Biochemical Sciences from Harvard College. Prior to her Industry career, Carole was on Faculty in the Department of Neurology at Stanford University. Carole currently serves on the Board of Directors of Beam Therapeutics.

What is Carole Ho's net worth?: The estimated net worth of Carole Ho is at least $3.86 million as of January 6th, 2025. Dr. Ho owns 178,580 shares of Denali Therapeutics stock worth more than $3,855,542 as of February 21st. This net worth evaluation does not reflect any other assets that Dr. Ho may own. Additionally, Dr. Ho receives a salary of $802,290.00 as Insider at Denali Therapeutics. Learn More about Carole Ho's net worth.
How old is Carole Ho?: Dr. Ho is currently 51 years old. There are 3 older executives and no younger executives at Denali Therapeutics. The oldest executive at Denali Therapeutics is Dr. Marc Tessier-Lavigne Ph.D., Co-Founder & Independent Director, who is 64 years old. Learn More on Carole Ho's age.
What is Carole Ho's salary?: As the Insider of Denali Therapeutics Inc., Dr. Ho earns $802,290.00 per year. The highest earning executive at Denali Therapeutics is Dr. Ryan J. Watts Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,150,000.00 per year. Learn More on Carole Ho's salary.
How do I contact Carole Ho?: The corporate mailing address for Dr. Ho and other Denali Therapeutics executives is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. Denali Therapeutics can also be reached via phone at (615) 866-8548 and via email at hansen@dnli.com. Learn More on Carole Ho's contact information.
Has Carole Ho been buying or selling shares of Denali Therapeutics?: During the last quarter, Carole Ho has sold $247,796.10 of Denali Therapeutics stock. Most recently, Carole Ho sold 12,255 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a transaction totalling $247,796.10. Following the completion of the sale, the insider now directly owns 178,580 shares of the company's stock, valued at $3,610,887.60. Learn More on Carole Ho's trading history.
Who are Denali Therapeutics' active insiders?: Denali Therapeutics' insider roster includes Jennifer Cook (Director), Carole Ho (Insider), Steve Krognes (CFO), Vicki Sato (Director), David Schenkein (Director), Alexander Schuth (COO), Marc Tessier-Lavigne (Director), and Ryan Watts (CEO). Learn More on Denali Therapeutics' active insiders.
Are insiders buying or selling shares of Denali Therapeutics?: In the last twelve months, insiders at the sold shares 13 times. They sold a total of 260,830 shares worth more than $6,084,876.79. The most recent insider tranaction occured on January, 7th when Director Steve E Krognes sold 3,339 shares worth more than $69,484.59. Insiders at Denali Therapeutics own 7.9% of the company. Learn More about insider trades at Denali Therapeutics.
Information on this page was last updated on 1/7/2025.

Carole Ho Insider Trading History at Denali Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/6/2025	Sell	12,255	$20.22	$247,796.10	178,580
2/13/2024	Sell	2,784	$17.29	$48,135.36	145,010
1/10/2024	Sell	4,668	$19.02	$88,785.36	147,794
1/5/2024	Sell	9,972	$19.43	$193,755.96	198,777
8/23/2023	Sell	2,522	$23.22	$58,560.84	182,809
8/21/2023	Sell	2,478	$22.60	$56,002.80	185,331
8/21/2023	Sell	2,478	$22.60	$56,002.80	185,331
8/14/2023	Sell	2,768	$23.79	$65,850.72	182,809
8/10/2023	Sell	2,857	$24.15	$68,996.55	185,577
2/13/2023	Sell	2,548	$30.10	$76,694.80	184,285
2/10/2023	Sell	818	$29.80	$24,376.40	179,365
2/8/2023	Sell	1,521	$30.88	$46,968.48	180,183
1/9/2023	Sell	1,459	$28.48	$41,552.32	177,454
1/6/2023	Sell	1,451	$28.67	$41,600.17	178,913
1/4/2023	Sell	2,913	$28.69	$83,573.97	175,500
8/23/2022	Sell	2,424	$31.98	$77,519.52	170,663
2/11/2022	Sell	2,918	$34.71	$101,283.78
1/5/2022	Sell	2,845	$44.78	$127,399.10
12/6/2021	Sell	1,476	$42.52	$62,759.52
8/23/2021	Sell	6,143	$48.91	$300,454.13
8/19/2021	Sell	2,546	$49.58	$126,230.68
3/29/2021	Sell	2,822	$54.62	$154,137.64
2/11/2021	Sell	3,156	$70.33	$221,961.48
2/9/2021	Sell	1,470	$74.68	$109,779.60	1,476
10/9/2020	Sell	30,000	$41.22	$1,236,600.00
9/10/2020	Sell	3,689	$31.00	$114,359.00
12/23/2019	Sell	3,464	$20.01	$69,314.64
12/19/2019	Sell	2,566	$20.00	$51,320.00
7/8/2019	Sell	17,500	$20.29	$355,075.00
6/10/2019	Sell	17,500	$18.78	$328,650.00
5/10/2019	Sell	17,500	$22.85	$399,875.00
3/14/2019	Sell	1,000	$25.01	$25,010.00
10/1/2018	Sell	17,500	$21.72	$380,100.00

See Full Table

Carole Ho Buying and Selling Activity at Denali Therapeutics

Denali Therapeutics Company Overview

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Today's Range

Now: $21.59

$21.50

$22.81

50 Day Range

MA: $21.67

$18.74

$23.59

2 Week Range

Now: $21.59

$14.56

$33.33

Volume

784,067 shs

Average Volume

959,881 shs

Market Capitalization

$3.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43

Carole Ho Biography and Net Worth

What is Carole Ho's net worth?

How old is Carole Ho?

What is Carole Ho's salary?

How do I contact Carole Ho?

Has Carole Ho been buying or selling shares of Denali Therapeutics?

Who are Denali Therapeutics' active insiders?

Are insiders buying or selling shares of Denali Therapeutics?